On April 22, 2026, the U.S. Food and Drug Administration (FDA) issued the "Class II Medical Sensors: Cybersecurity and Biocompatibility Guidance Update", clearly requiring that from June 1, 2026, all medical pressure, temperature, and bioimpedance sensors exported to the United States must pass the newly added cybersecurity validation (IEC 62304 Annex C) and biocompatibility testing for skin-contact materials (ISO 10993-5/10). This update directly affects Chinese sensor manufacturers supplying European and American medical device OEMs, especially manufacturers such as Xi'an Shenghongchuang that are qualified to export Class II sensors, whose export market access and customer factory audit procedures will face substantial adjustments.

Event Overview

On April 22, 2026, the U.S. FDA officially released the "Class II Medical Sensors: Cybersecurity and Biocompatibility Guidance Update". This document is a mandatory compliance guideline applicable to Class II medical sensors intended to enter the U.S. market, specifically including three categories: pressure sensors, temperature sensors, and bioimpedance sensors. The new regulation takes effect from June 1, 2026, requiring the relevant products to complete two new validations before market launch: first, a cybersecurity lifecycle assessment in accordance with Annex C of the IEC 62304 standard; second, a biological evaluation of all materials expected to come into contact with skin or mucosa in accordance with ISO 10993-5 (cytotoxicity) and ISO 10993-10 (irritation and sensitization). The document has been publicly released through the FDA official website, with no transition period exemption clauses established.

Which market segments will be affected

Direct trading enterprises: Trading companies engaged in exporting medical sensors to the United States must supplement customs declaration documents, FDA listing (Listing), and 510(k) submission materials with cybersecurity statements and biocompatibility reports. The impact is mainly reflected in longer customs clearance timelines, increased risk of customer rejection, and the possibility that traceability of third-party testing report validity periods may trigger supplementary inspection requirements for historical orders.

Processing and manufacturing enterprises: Manufacturers represented by Xi'an Shenghongchuang that provide customized sensor modules for European and American OEMs need to simultaneously adjust product design documentation (such as software architecture diagrams and material composition tables), change records in the quality management system (QMS), and cooperate with customers to complete a new round of factory audits (such as FDA on-site inspections or OEM supplier audits). The impact is concentrated in compressed R&D cycles, increased testing costs, and greater difficulty in consistency control of mass production batches.

Supply chain service enterprises: Service providers offering testing and certification agency services, regulatory consulting, or localized registration support for sensor manufacturers will face short-term business pressure—as a large number of customers simultaneously initiate IEC 62304 Annex C assessments and ISO 10993 testing, resulting in tight scheduling at third-party laboratories, longer report issuance cycles, and practical tests for service capacity.

What key points should relevant enterprises or practitioners pay attention to, and how should they respond at present

Immediately verify the contact interfaces and software layers of in-production/in-development sensors

Confirm whether the product has components in direct contact with skin/mucosa (such as patch electrodes and sealing materials at the ends of catheters), and identify whether it contains embedded software (including firmware upgrade functions or wireless communication modules). Merely meeting hardware electrical safety requirements (such as IEC 60601) is no longer sufficient to support compliance submissions.

Prioritize connecting with testing institutions already recognized by the FDA to initiate pre-assessment

Focus on practical steps such as "threat modeling" and "vulnerability response process" required under IEC 62304 Annex C, as well as extract preparation and cell line selection required under ISO 10993-5/10, to avoid repeat sample submissions caused by deviations in the testing plan. It is recommended to prioritize laboratories that are qualified for both IEC 62304 and ISO 10993, so as to shorten the coordination cycle.

Review the compliance responsibility clauses in existing OEM contracts

Check the provisions in technical agreements or quality agreements regarding "obligations to respond to regulatory changes", "ownership of testing reports", and "mechanisms for sharing rectification costs", with particular attention to whether it is agreed that the supplier alone shall bear the newly added testing costs, or whether a delivery grace period may be triggered due to compliance delays.

Establish an internal backward schedule before June 1

Work backward from the latest testing submission date, reserving at least 45 days for the testing cycle, 15 days for report review and document integration, and a 7-day window for customer communication and feedback, ensuring that all technical document updates and FDA system information synchronization are completed before June 1.

Editorial Viewpoint / Industry Observation

From an industry perspective, this FDA update is more like a "raising of the compliance baseline" rather than a sudden regulatory crackdown. Its core logic is to incorporate Class II sensors into a cybersecurity and biosafety management framework aligned with higher-risk devices, reflecting a renewed regulatory understanding of the risks of integrated devices combining "connectivity + contact". Analysis suggests that this guidance will not change the overall volume of market access in the short term, but it will accelerate the differentiation of export enterprises: companies with complete software lifecycle management capabilities and material databases will gain more stable OEM cooperation positions; while small and medium-sized manufacturers that rely on outsourced testing and lack independent validation capabilities may face pressure from order transfers. What is currently more worthy of attention is whether the FDA will subsequently issue a FAQ document on the implementation details of Annex C (such as the minimum software complexity threshold), which will directly affect the prioritization of enterprise resource investment.

Conclusion:
This FDA guidance update is not an isolated policy action, but rather a concrete manifestation of the evolution of global medical device regulation toward "full lifecycle data traceability and controllable human-machine interaction risks". For Chinese export enterprises, it not only constitutes a rigid compliance deadline before June, but also indicates a long-term trend: sensors are no longer merely functional components, but system-level components that carry cybersecurity responsibilities and clinical biosafety commitments. At present, it is more appropriate to understand this as an adaptive adjustment to clear rules, rather than an unpredictable regulatory shift.

Description of information sources:
Main source: the "Class II Medical Sensors: Cybersecurity and Biocompatibility Guidance Update" published on the official FDA website (release date: April 22, 2026)
Items for continued observation: whether the FDA will issue supplementary explanations on the scope of application of IEC 62304 Annex C in Class II sensors; and changes in the actual response capacity of third-party testing institutions regarding ISO 10993-5/10 testing cycles.